CN114681587A

CN114681587A - Product for preventing and treating hyperuricemia and gouty arthritis and preparation method thereof

Info

Publication number: CN114681587A
Application number: CN202210405514.XA
Authority: CN
Inventors: 刘扬; 龙秀红; 王炎冰; 潘建文
Original assignee: Guangdong Shinyee Marine Biology Engineering Corp
Current assignee: Guangdong Shinyee Marine Biology Engineering Corp
Priority date: 2022-04-18
Filing date: 2022-04-18
Publication date: 2022-07-01

Abstract

The invention relates to A61K 38/02, in particular to a product for preventing and treating hyperuricemia and gouty arthritis and a preparation method thereof, and the product at least comprises the following raw materials: natural plant powder, oligosaccharide, and peptide powder. The product for preventing and treating hyperuricemia and gouty arthritis provided by the invention can effectively reduce serum urea nitrogen, blood uric acid and blood creatinine, relieve gouty joint pain, reduce the occurrence of hyperuricemia and gouty arthritis, repair liver and kidney and reduce toxic and side effects of western medicines.

Description

Product for preventing and treating hyperuricemia and gouty arthritis and preparation method thereof

Technical Field

The invention relates to A61K 38/02, in particular to a product for preventing and treating hyperuricemia and gouty arthritis and a preparation method thereof.

Background

Hyperuricemia has become the 'fourth high' after the 'third high' disease, the main excretion channel of uric acid is the kidney, and when the uric acid value exceeds the metabolic limit of the kidney, urate can be crystallized and precipitated in joint cavities, so that symptoms such as joint pain, joint red swelling and the like appear, and gouty arthritis is induced. The general quality methods are physical treatment and drug treatment, the physical treatment cannot solve the problems fundamentally and only can relieve gout symptoms; drug resistance and adverse reactions are easy to generate in drug treatment.

Patent CN201510252129.6 composite superfine powder for preventing and treating gout and hyperuricemia and a preparation method thereof adopt dendrobium nobile lindl, dendrobium chrysanthum, gorgon fruit, coix seed, kudzu root, lotus leaf and cinnamon as raw materials and adopt a superfine powder preparation technology to obtain a product which can effectively reduce the content of blood uric acid of a patient and relieve pain.

Patent CN202110500995.8 discloses a product for reducing uric acid and promoting dissolution of tophus, a preparation method thereof and a product prepared by using chicory powder, green plum powder, mulberry leaf powder, gardenia powder, gynura procumbens powder and rhizoma smilacis glabrae powder as raw materials, which effectively reduce the generation of uric acid and promote the dissolution of tophus.

However, the product prepared in the prior art has limited effect on preventing and treating hyperuricemia and gouty arthritis, and cannot radically reduce the generation of uric acid and reduce the contents of serum urea nitrogen, blood uric acid and blood creatinine in a body.

Disclosure of Invention

In order to solve the technical problems, the invention provides a product for preventing and treating hyperuricemia and gouty arthritis, which at least comprises the following raw materials: natural plant powder, oligosaccharide and peptide powder.

Preferably, the product for preventing and treating hyperuricemia and gouty arthritis further comprises sugar alcohol and a sweetening agent.

Preferably, the raw materials comprise, by mass, 80-100 parts of natural plant powder, 35-50 parts of oligosaccharide, 150 parts of peptide powder, 25-35 parts of sugar alcohol and 0.5-1 part of sweetener.

Preferably, the natural plant powder has an average particle size of 80 to 160 mesh.

Preferably, the natural plant powder comprises at least one of inulin, sweet orange powder, lemon powder, hawthorn powder, acerola powder, mangosteen powder, passion fruit powder, medlar powder, tuckahoe powder, salvia powder, pearl barley powder, kudzu root powder, wild jujube kernel powder, green tea powder, rhizoma polygonati powder, pseudo-ginseng powder, turmeric powder, cassia seed powder, lotus leaf powder, navy bean powder, drumstick tree leaf powder and husk powder and plantain seed.

Preferably, the natural plant powder at least comprises acerola powder, mangosteen powder, medlar powder, tuckahoe powder, pearl barley powder, yellow essence powder and turmeric powder. The mass ratio of the acerola powder, the mangosteen powder, the medlar powder, the tuckahoe powder, the pearl barley powder, the rhizoma polygonati powder and the turmeric powder is (20-35): (8-17): (2-5): (10-15): (10-15): (1-3): (2-7).

Preferably, the content of mangosteen polyphenol in the mangosteen powder is 30-50%, and the content of alpha-mangostin is 20-40%.

Preferably, the content of the lycium barbarum polysaccharide in the lycium barbarum powder is 45-55%.

Preferably, the pachymaran content in the Poria cocos powder is 20-40%.

Preferably, the content of polygonatum polysaccharide in the polygonatum powder is 45-55%.

Preferably, the turmeric powder gingerol content is 5-15%.

In a preferred embodiment, the natural plant powder comprises inulin, sweet orange powder, lemon powder, acerola powder, mangosteen powder, passion fruit powder, medlar powder, tuckahoe powder, pearl barley powder, rhizoma polygonati powder, cassia seed powder and lotus leaf powder.

In a more preferred embodiment, the natural plant powder comprises the following raw materials by weight: 30-35 parts of inulin, 10-15 parts of sweet orange powder, 15-20 parts of lemon powder, 20-35 parts of acerola powder, 8-17 parts of mangosteen powder, 1-3 parts of passion fruit powder, 2-5 parts of medlar powder, 10-15 parts of tuckahoe powder, 10-15 parts of pearl barley powder, 1-3 parts of rhizoma polygonati powder, 2-7 parts of turmeric powder, 1-2 parts of cassia seed powder and 1-2 parts of lotus leaf powder.

In a preferred embodiment, the natural plant powder comprises lemon powder, acerola powder, mangosteen powder, medlar powder, tuckahoe powder, pearl barley powder, rhizoma polygonati powder, ginger powder, cassia seed powder, lotus leaf powder, navy bean powder and psyllium husk powder.

In a preferred embodiment, the natural plant meal material comprises: according to the mass parts, the lemon powder is 15-20 parts, the acerola cherry powder is 20-35 parts, the mangosteen powder is 8-17 parts, the medlar powder is 2-5 parts, the tuckahoe powder is 10-15 parts, the pearl barley powder is 10-15 parts, the yellow powder is 1-3 parts, and the turmeric powder is 2-7 parts.

In a more preferred embodiment, each raw material of the natural plant powder further comprises 5-8 parts of compound powder. The compound powder comprises semen Cassiae powder, folium Nelumbinis powder, navy bean powder, and Plantago ovata husk powder.

Preferably, the oligosaccharide comprises at least one of maltooligosaccharide, fructooligosaccharide, lactooligosaccharide, xylooligosaccharide, oligochitosan, algal oligosaccharide and soybean oligosaccharide.

Further preferably, the oligosaccharide comprises fructooligosaccharide and chitosan oligosaccharide. The mass ratio of the fructo-oligosaccharide to the chitosan oligosaccharide is (20-30): (15-20).

Preferably, the fructooligosaccharide is a G-type fructooligosaccharide and/or a P-type fructooligosaccharide.

Preferably, the average molecular weight of the chitosan oligosaccharide is less than 5000 Da.

Preferably, the chitosan oligosaccharide comprises a first chitosan oligosaccharide and a second chitosan oligosaccharide. The mass ratio of the first chitosan oligosaccharide to the second chitosan oligosaccharide is (2-4): (3-5).

Preferably, the first oligochitosan has an average molecular weight of 2000-3000 Da.

Preferably, the second oligochitosan has an average molecular weight of 800-1500 Da.

Preferably, the protein content in the peptide powder is more than or equal to 80%.

Preferably, the peptide powder is tuna peptide powder.

Preferably, the sugar alcohol comprises at least one of sorbitol, mannitol, erythritol, maltitol, lactitol, xylitol.

Further preferably, the sugar alcohol is sorbitol.

Preferably, the sweetener comprises at least one of aspartame, saccharin, mogroside, stevioside, rubusoside, glycyrrhizin.

Further preferably, the sweetener is saccharin.

The second aspect of the invention provides a preparation method of a product for preventing and treating hyperuricemia and gouty arthritis, which comprises the following steps: weighing the raw materials according to the mass, and uniformly mixing the raw materials to obtain the composition.

Has the advantages that:

1) the product prepared by compounding different kinds of natural plant powder, peptide powder and oligosaccharide can effectively reduce serum urea nitrogen, blood uric acid and blood creatinine, reduce joint pain and reduce the occurrence of hyperuricemia and gouty arthritis.

2) Impaired kidney function is one of the major causes of persistent reduction in uric acid output, and the onset of hyperuricemia and gouty arthritis. The acerola cherry powder, the mangosteen powder, the medlar powder, the tuckahoe powder, the pearl barley powder, the rhizoma polygonati powder and the turmeric powder are compounded, and particularly when the mass ratio is (20-35): (8-17): (2-5): (10-15): (10-15): (1-3): (2-7), the composition can effectively reduce the phenomenon of kidney function damage caused by diabetes, simultaneously improve SOD activity, diminish inflammation, promote urination, balance serum urea nitrogen and creatinine indexes, reduce reabsorption of renal tubules, promote the excretion of urate in vitro, simultaneously reduce inflammation, slow the attack of gouty arthritis and relieve pain during the attack.

3) The tuna peptide powder is further adopted, so that the lactic acid content is reduced, the formation of crystals is avoided, the regulation of intestines and stomach is facilitated, gout drugs are prevented from damaging human bodies, the gastrointestinal absorption of various nutrients is promoted, meanwhile, the tuna peptide powder and the oligochitosan with the average molecular weight of 2500Da and 1000Da have the combined action to inhibit the activity of uric acid generating enzyme, and the free radicals are removed and the generation of hypoxanthine is reduced by combining acerola powder, mangosteen powder, medlar powder, tuckahoe powder, pearl barley powder, yellow fine powder and turmeric powder in a system, so that the generation of uric acid is fundamentally reduced, liver cells are improved, and the damage to liver functions is reduced.

4) The invention adopts the sorbitol to accelerate gastrointestinal peristalsis, increase excretion times and promote uric acid excretion, and the medlar powder, the tuckahoe powder, the pearl barley powder and the like accelerate gastrointestinal peristalsis, promote urination, further reduce reabsorption of renal tubules and promote uric acid excretion from the body.

Description of the drawings:

FIG. 1 pathological examination-Normal control renal histogram;

FIG. 2 pathology examination-Normal control group liver histogram;

figure 3 pathology examination-kidney histogram of model control group;

FIG. 4 pathological examination-model control group liver histogram;

FIG. 5 pathological examination-positive control renal histogram;

FIG. 6 pathological examination-Deprolin control group renal histogram;

fig. 7 pathology examination-low dose group kidney histogram;

fig. 8 pathology examination-medium dose group kidney histogram;

fig. 9 pathology examination-high dose group kidney histogram;

FIG. 10 staining test-Normal control group Kidney tissue map;

FIG. 11 staining examination-renal histology map of model control group;

FIG. 12 staining check-positive control renal histology map;

FIG. 13 staining check-prodiamine control renal histogram;

FIG. 14 staining examination-Low dose group Kidney histology map;

figure 15 staining exam-middle dose group renal histology map;

figure 16 staining exam-high dose group renal histology map.

Detailed Description

The natural plant powder sources are as follows:

the medlar powder, tuckahoe powder and sealwort powder are purchased from Shaanxi Sinot biotechnology limited company.

The inulin was purchased from Kyoho Hongrun Biotech limited.

The sweet orange powder and the passion fruit powder Tianjin are from Zhenhuo food industry Co.

The acerola cherry powder has a vitamin C content of 25% and is available from Walt Laisi Biotech, Inc., Lanzhou.

The coix seed powder is purchased from walteris biotechnology limited, lanzhou.

The content of mangosteen polyphenol in the mangosteen powder is 40%, and the content of alpha-mangostin is 30%. Purchased from Shanxi Kokai Biotech Co., Ltd. The tuckahoe powder is purchased from Shaanxi Scoop Biotech limited company.

The yellow refined powder is purchased from Shaanxi Hongze bioengineering limited company.

The turmeric powder contains gingerol 10%, and is purchased from bioscience and technology limited company of West Anxi sea.

If not specifically stated, the specification of the natural plant powder is 10:1, and the average particle size is 80-160 meshes.

Examples

Example 1

A product for preventing and treating hyperuricemia and gouty arthritis comprises the following raw materials: the beverage comprises 90 parts by mass of natural plant powder, 42 parts by mass of oligosaccharide, 135 parts by mass of peptide powder, 30 parts by mass of sugar alcohol and 0.8 part by mass of sweetener.

The natural plant powder comprises the following raw materials in percentage by weight: the health-care tea comprises, by mass, 32 parts of inulin, 12 parts of sweet orange powder, 17 parts of lemon powder, 28 parts of acerola cherry powder, 12 parts of mangosteen powder, 2 parts of passion fruit powder, 3 parts of Chinese wolfberry powder, 12 parts of poria cocos powder, 13 parts of coix seed powder, 2 parts of yellow fine powder, 3 parts of turmeric powder, 1.5 parts of cassia seed powder and 1.5 parts of lotus leaf powder.

The cassia seed powder is purchased from the fenugreek organism.

The lotus leaf powder was purchased from walteris biotechnology limited, lanzhou.

The oligosaccharide comprises fructo-oligosaccharide and chitosan oligosaccharide. The mass ratio of the fructo-oligosaccharide to the chitosan oligosaccharide is 25: 17.

the fructo-oligosaccharide is P-type fructo-oligosaccharide, and is purchased from Nantong Tianxiang bioengineering Co.

The chitosan oligosaccharide comprises a first chitosan oligosaccharide and a second chitosan oligosaccharide. The mass ratio of the first chitosan oligosaccharide to the second chitosan oligosaccharide is 3: 4. the average molecular weight of the first chitosan oligosaccharide is 2500Da, and the average molecular weight of the second chitosan oligosaccharide is 1000 Da.

The protein content in the peptide powder is more than or equal to 80%, and the peptide powder is tuna peptide powder (anserine 240Da) and is derived from Zhaoqingxingyi marine organisms.

The sugar alcohol is sorbitol.

The sweetener is saccharin.

A preparation method of a product for preventing and treating hyperuricemia and gouty arthritis comprises the following steps: weighing the raw materials according to the mass, and uniformly mixing the raw materials to obtain the composition.

Example 2

The specific implementation mode of the product for preventing and treating hyperuricemia and gouty arthritis is the same as that in example 1, except that the natural plant powder comprises the following raw materials in parts by weight: according to the mass parts, the traditional Chinese medicine composition comprises 18 parts of lemon powder, 27 parts of acerola cherry powder, 13 parts of mangosteen powder, 3 parts of medlar powder, 12 parts of tuckahoe powder, 13 parts of pearl barley powder, 2 parts of yellow fine powder, 3 parts of turmeric powder and 7 parts of compound powder. The compound powder comprises cassia seed powder, lotus leaf powder, navy bean powder and psyllium seed shell powder, and is purchased from Xian Ruibo biotechnology limited company.

Example 3

The specific implementation mode of the product for preventing and treating hyperuricemia and gouty arthritis is the same as that in example 1, and the difference is that the raw materials comprise 100 parts of natural plant powder, 50 parts of oligosaccharide, 150 parts of peptide powder, 35 parts of sugar alcohol and 1 part of sweetener.

Example 4

The specific implementation mode of the product for preventing and treating hyperuricemia and gouty arthritis is the same as that in example 1, except that the mass ratio of the fructo-oligosaccharide to the chitosan oligosaccharide is 25: 25.

example 5

The specific implementation mode of the product for preventing and treating hyperuricemia and gouty arthritis is the same as that in example 1, except that the natural plant powder comprises the following raw materials in parts by weight: the health-care tea comprises, by mass, 32 parts of inulin, 12 parts of sweet orange powder, 17 parts of lemon powder, 28 parts of acerola cherry powder, 5 parts of mangosteen powder, 2 parts of passion fruit powder, 3 parts of medlar powder, 12 parts of poria cocos powder, 13 parts of pearl barley powder, 2 parts of yellow powder, 1 part of turmeric powder, 1.5 parts of cassia seed powder and 1.5 parts of lotus leaf powder.

Performance testing

1. Example 1 blood index test: 63 male SD rats weighing 190.9-230.9 were selected and divided into seven groups (normal group, model control group, positive control group, souring-lowering control group, and low, medium, and high dose groups in example 1), 9 groups were tested as described in Table 1, except for the normal control group, the animals in each group were gavaged with 50mg/mL adenine solution (250mg/kg body weight) per day at mL/kg body weight, and the animals in the normal control group were gavaged with purified water 1 time per day for 14 consecutive days. And after the product is separated from the gavage for 3 hours or more, the positive control group and the souring-reducing control group are respectively gavage with allopurinol tablet liquid medicine, the souring-reducing liquid medicine, the normal control group and the model control group with the same volume of purified water for 1 time/day according to the corresponding dose of the product in the example 1 of the gavage of 10mL/kg body weight.

TABLE 1

TABLE 2 serum Urea Nitrogen test results

TABLE 3 blood uric acid test results

Table 4 serum creatinine assay results

2. Example 1 histopathological testing

According to GDMLAC/SOP-PAT24 microscope observation of pathological section, after continuous administration for 30 days according to the method provided in blood index test, the animal liver and the right kidney are fixed by 4% neutral formaldehyde and then undergo histopathological examination and anhydrous alcohol fixation and then undergo urate staining examination, and the histological morphology of the liver and the kidney and the deposition condition of the kidney urate of each group of experimental animals are observed.

TABLE 5 tubulointerstitial injury Scoring Standard

TABLE 6 tubulointerstitial injury score results

Note: using the rank sum test analysis above, "·" indicates that P < 0.05 compared to the normal control group.

TABLE 7 mean optical Density value scoring results for urate

Note: using one-way ANOVA as described above, ". cndot.represents P < 0.05 as compared to the normal control and,". cndot.represents P < 0.05 as compared to the model control.

2. And (3) stability testing: weighing an example sample with the mass of m1, placing the example sample in a beaker, placing the beaker for 2 days at the temperature of 30 ℃ and the humidity of 90%, sieving the sample, and drying the sieved sample in an oven to the constant weight of m2, wherein the caking rate is 100% (m1-m2)/m 1).

	Caking rate%
		Example 1	0.7
Example 2	0.9
		Example 3	0.9
Example 4	0.8
		Example 5	1

Claims

1. A product for preventing and treating hyperuricemia and gouty arthritis is characterized by at least comprising the following raw materials: natural plant powder, oligosaccharide and peptide powder.

2. The product of claim 1, wherein the natural plant powder comprises at least one of inulin, sweet orange powder, lemon powder, hawthorn powder, acerola powder, mangosteen powder, passion fruit powder, medlar powder, tuckahoe powder, salvia miltiorrhiza powder, pearl barley powder, pueraria powder, wild jujube kernel powder, green tea powder, rhizoma polygonati powder, pseudo-ginseng powder, turmeric powder, cassia seed powder, lotus leaf powder, navy bean powder, drumstick tree leaf powder and psyllium husk powder.

3. The product as claimed in claim 1, wherein the natural plant powder has an average particle size of 80-160 mesh.

4. The product for preventing and treating hyperuricemia and gouty arthritis according to claim 1, wherein the oligosaccharide comprises at least one of maltooligosaccharide, fructooligosaccharide, lactooligosaccharide, xylooligosaccharide, oligochitosan, algal oligosaccharide and soybean oligosaccharide.

5. The product for preventing and treating hyperuricemia and gouty arthritis according to claim 1, wherein the protein content in the peptide powder is not less than 80%.

6. The product for preventing and treating hyperuricemia and gouty arthritis according to any one of claims 1 to 5, wherein the raw materials further comprise sugar alcohol and a sweetener.

7. The product as claimed in claim 6, wherein the raw materials include, by weight, 80-100 parts of natural plant powder, 35-50 parts of oligosaccharide, 120-150 parts of peptide powder, 25-35 parts of sugar alcohol, and 0.5-1 part of sweetener.

8. The product of claim 6, wherein the sugar alcohol comprises at least one of sorbitol, mannitol, erythritol, maltitol, lactitol, and xylitol.

9. The product for preventing and treating hyperuricemia and gouty arthritis according to claim 6, wherein the sweetening agent comprises at least one of aspartame, saccharin, mogroside, stevioside, rubusoside and glycyrrhizin.

10. The preparation method of the product for preventing and treating hyperuricemia and gouty arthritis according to claim 7, which comprises the following steps: weighing the raw materials according to the mass, and uniformly mixing the raw materials to obtain the composite material.